MEDICAL RESEARCH BLOG
welcome
The purpose of this space is to inform the community — both health professionals and patients and their caregivers — about advances in medical research related to Chronic Kidney Disease (CKD) and the role that intermediary metabolites of the Krebs cycle and other treatments play in counteracting the deterioration of kidney function. We trust that the medical community is interested in learning about and analyzing all available options today.
3
Verified information by 3 medical fields: nephrology, internal medicine, and endocrinology.
+50
More than 50 scientific articles analyzed to provide you with complete, substantial, truthful, and reliable information.
2024
Information presented is updated through 2024 with the latest KDIGO guidelines and the most recent discoveries.
thank you
Thank you for your interest in our blog. If you have any questions or comments, please fill out the contact form and we will get in touch with you shortly.
Why is CKD so relevant?
Chronic Kidney Disease (CKD) is a global health crisis (Levey AS, Atkins R, et al.) because 1 in 10 adults has some degree of CKD (stages I to V), and it ranks #7 among the top 10 causes of death among non-communicable diseases worldwide (WorldKidneyDay.org).
CKD is considered a catastrophic public health situation for five main reasons:
(Treviño BA, 2004 / Paniagua R, 2007)
Growing Number of Cases
Approximately 700 million people suffer from CKD worldwide (Nature.com).
In 2004, globally, the prevalence of patients on renal replacement therapy was about 1.8 million patients, that is, 215 patients per million inhabitants (López Cervantes, 2010).
High Costs
In England, according to a study, CKD costs more than the combined treatment of breast, lung, colon, and skin cancers (WorldKidneyDay.Org).
According to the Renal Data System 2012 of the United States, the annual cost of treating a patient on hemodialysis is about $87,000 USD, or about $7,250 USD per month.
Limited Infrastructure and Staff
Dialysis sessions are shortened to accommodate more patients due to shortages of nephrologists, technicians, nurses, surgeons, and support staff (Prasad N, Jha V, 2015).
In Mexico, more than 129,000 patients require life-sustaining renal replacement therapy, but only about half receive some form of treatment (López Cervantes, 2010).
Late Detection
CKD is a silent disease — people show no signs or symptoms until the final stages (WorldKidneyDay.Org).
In as little as 2 to 3 years, kidney function can decline from 30% down to 15%.
High morbidity and mortality rates on dialysis
In Mexico, survival was about 30.6 months on peritoneal dialysis and 32 months on hemodialysis (Méndez-Durán, et al. 2010).
Reports from the Mexican Social Security Institute (IMSS) list CKD among the top 10 causes of hospital deaths.